Press Releases 2013
FDA Advisory Panel Votes Favorably on the Boston Scientific WATCHMAN™ Left Atrial Appendage Closure Device - Dec 11, 2013
"We are pleased with the outcome of today's Panel, which represents an important milestone toward making this innovative technology available to patients with AF at higher risk for stroke...
First enrolment in EWOLUTION registry to collect real world clinical outcomes for Boston Scientific WATCHMAN™ Left Atrial Appendage closure technology - Oct 30, 2013
The EWOLUTION Registry is a multi-national post market data collection on procedural success, incidence of stroke and mortality of patients implanted with a WATCHMAN™ device.
Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 - May 17, 2013
"We are pleased to present a particularly rich and diversified set of data this year at EuroPCR," said Keith Dawkins, M.D., global chief medical officer, Boston Scientific. "The primary endpoint results...
New Four-Year Data From Boston Scientific Demonstrated WATCHMAN™ Device Was Superior To Warfarin For Mortality And Primary Efficacy In Patients With Atrial Fibrillation In Long Term Follow-Up Of The PROTECT AF Trial - May 09, 2013
Boston Scientific Corporation (NYSE: BSX) reports that the four-year follow-up data from the PROTECT AF clinical trial demonstrated the WATCHMAN® Left Atrial Appendage (LAA)...
Presentation of Preliminary Results From Boston Scientific PREVAIL Clinical Trial Now Available - Mar 09, 2013
Boston Scientific Corporation (NYSE: BSX) announces the preliminary analysis of the PREVAIL clinical trial data is now available on TCTMD at https://www.tctmd.com/show.aspx...
The Boston Scientific Watchman™ Device Continues To Demonstrate Positive Clinical Outcomes For Patients With Atrial Fibrillation - Mar 09, 2013
The PREVAIL trial evaluates safety and efficacy of the WATCHMAN® Left Atrial Appendage (LAA) Closure device in patients with nonvalvular atrial fibrillation versus long-term...
Boston Scientific Updates PREVAIL Late Breaking Clinical Trials Presentation - Mar 06, 2013
The Boston Scientific Corporation (NYSE: BSX) PREVAIL clinical trial results will be presented in a Late-Breaking Clinical Trial presentation at the 62nd Annual Scientific Sessions of the...